LNTH

+ Watchlist + Portfolio

Lantheus Holdings, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $100.48
52-Week Range: $49.67 – $111.86
Market Cap: $6.54B
P/E (TTM): 23.98
EPS (TTM): 4.18
Dividend Yield: —

Advanced Metrics

Price/Book: 4.99
PEG Ratio: —
Return on Equity: 22.21%
Return on Assets: 8.38%
Gross Margin: 60.14%
Operating Margin: 25.82%
Profit Margin: 17.69%
Current Ratio: 3.06
Debt/Equity: 0.48
Total Debt: $624.96M
Free Cash Flow: $451.66M
Revenue Growth: 2.70%
Earnings Growth: -0.90%
Enterprise Value: $6.58B

LNTH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$935.06M	$1.30B	$1.53B	$1.54B
Cost of Revenue	$353.36M	$586.89M	$545.62M	$599.66M
Gross Profit	$581.70M	$709.54M	$988.29M	$941.95M
Research & Development	$311.68M	$77.71M	$168.10M	$177.31M
Selling, General & Admin	$233.83M	$267.19M	$371.63M	$453.81M
Operating Expenses	$545.51M	$344.90M	$539.73M	$626.39M
Operating Income	$36.20M	$364.64M	$448.56M	$315.56M
EBITDA	$81.83M	$491.00M	$515.27M	$403.64M
Pretax Income	$26.72M	$410.94M	$430.98M	$313.79M
Income Tax	-$1.35M	$84.28M	$118.53M	$80.23M
Net Income	$28.07M	$326.66M	$312.44M	$233.56M
Diluted EPS	0.40	4.65	4.36	3.41
Diluted Shares	70.67M	70.24M	71.65M	68.44M

LNTH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$415.65M	$713.66M	$912.81M	$359.12M
Receivables	$213.40M	$284.29M	$329.44M	$374.03M
Inventory	$35.48M	$64.03M	$68.03M	$64.67M
Current Assets	$677.62M	$1.09B	$1.33B	$899.96M
Total Assets	$1.32B	$1.65B	$1.98B	$2.23B
Current Liabilities	$247.70M	$187.35M	$240.53M	$333.42M
Long-Term Debt	$557.71M	$561.67M	$565.28M	$568.68M
Total Debt	$583.51M	$616.95M	$619.44M	$619.43M
Total Liabilities	$874.11M	$835.26M	$892.33M	$1.14B
Retained Earnings	-$193.16M	$133.50M	$445.94M	$679.50M
Shareholders' Equity	$447.15M	$815.89M	$1.09B	$1.09B
Working Capital	$429.92M	$898.47M	$1.09B	$566.54M
Net Debt	$142.41M	—	—	$210.29M

LNTH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$281.78M	$305.26M	$544.75M	$390.14M
Capital Expenditure	-$18.35M	-$46.55M	-$79.63M	-$41.50M
Free Cash Flow	$263.43M	$258.70M	$465.13M	$348.64M
Depreciation & Amortisation	$47.93M	$60.04M	$64.62M	$70.10M
Stock-Based Compensation	$29.26M	$50.51M	$76.39M	$85.56M
Investing Cash Flow	-$276.55M	$5.94M	-$226.01M	-$627.17M
Financing Cash Flow	$311.69M	-$13.06M	-$118.54M	-$316.58M
Share Repurchases	-$75.00M	$0.00	-$100.00M	-$300.02M
Net Change in Cash	$316.93M	$298.14M	$200.20M	-$553.61M

LNTH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$372.76M	$378.05M	$384.01M	$406.79M	$377.33M
Cost of Revenue	$135.06M	$137.03M	$161.65M	$165.91M	$146.41M
Gross Profit	$237.70M	$241.01M	$222.37M	$240.88M	$230.92M
Research & Development	$36.31M	$45.49M	$48.02M	$47.48M	$39.38M
Selling, General & Admin	$99.32M	$107.56M	$130.73M	$116.21M	$110.22M
Operating Expenses	$130.91M	$153.04M	$178.75M	$163.69M	$149.60M
Operating Income	$106.79M	$87.97M	$43.62M	$77.18M	$81.33M
EBITDA	$114.96M	$122.67M	$67.74M	$98.28M	$183.95M
Pretax Income	$96.53M	$104.52M	$42.38M	$70.36M	$156.41M
Income Tax	$23.58M	$25.76M	$14.61M	$16.28M	$37.99M
Net Income	$72.94M	$78.75M	$27.77M	$54.09M	$118.42M
Diluted EPS	1.02	1.12	0.41	0.82	1.80
Diluted Shares	71.46M	70.31M	67.66M	66.31M	65.77M

LNTH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$938.53M	$695.57M	$382.01M	$359.12M	$498.58M
Receivables	$348.75M	$336.58M	$383.25M	$374.03M	$357.15M
Inventory	$69.13M	$62.16M	$62.04M	$64.67M	$61.34M
Current Assets	$1.42B	$1.20B	$925.09M	$899.96M	$942.29M
Total Assets	$2.06B	$2.12B	$2.28B	$2.23B	$2.35B
Current Liabilities	$248.00M	$280.13M	$346.84M	$333.42M	$333.17M
Long-Term Debt	$566.10M	$566.85M	$567.94M	$568.68M	$569.60M
Total Debt	$614.40M	$615.49M	$619.44M	$619.43M	$625.75M
Total Liabilities	$891.03M	$949.29M	$1.16B	$1.14B	$1.13B
Retained Earnings	$518.89M	$597.64M	$625.42M	$679.50M	$797.92M
Shareholders' Equity	$1.16B	$1.17B	$1.12B	$1.09B	$1.21B
Working Capital	$1.18B	$921.68M	$578.25M	$566.54M	$609.12M
Net Debt	—	—	$186.80M	$210.29M	$71.83M

LNTH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$107.56M	$87.11M	$105.29M	$90.18M	$125.13M
Capital Expenditure	-$8.72M	-$13.37M	-$10.62M	-$8.79M	-$3.23M
Free Cash Flow	$98.84M	$73.73M	$94.67M	$81.39M	$121.90M
Depreciation & Amortisation	$13.63M	$13.23M	$20.41M	$22.83M	$22.68M
Stock-Based Compensation	$21.20M	$22.32M	$24.50M	$17.54M	$16.04M
Investing Cash Flow	-$63.72M	-$232.47M	-$319.47M	-$11.51M	$25.99M
Financing Cash Flow	-$18.22M	-$98.41M	-$99.17M	-$100.79M	-$11.62M
Share Repurchases	—	—	-$100.00M	-$100.02M	—
Net Change in Cash	$25.63M	-$243.78M	-$313.34M	-$22.12M	$139.49M

Market Snapshot

About

Lantheus Holdings, Inc. is a medical imaging and radiopharmaceutical company focused on diagnostic and therapeutic applications. The company develops, manufactures, and commercializes innovative imaging agents used in nuclear medicine procedures to diagnose and treat various medical conditions. Lantheus' key products include DEFINITY for cardiac ultrasound imaging and Pylarify, a prostate-specific membrane antigen (PSMA) PET imaging agent for prostate cancer detection. The company serves hospitals, clinics, and imaging centers worldwide with specialized pharmaceutical products that enable physicians to make more informed diagnostic decisions.